MedTrace Logo

Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System

NCT00722241 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2008-07-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects \>18 years-old with diabetes mellitus requiring insulin therapy.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • DexCom, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrew K Balo, BS · DexCom, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-06-30
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722241 on ClinicalTrials.gov